Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.
Increase effective retroactively to January 1, 2026; initial payment includes catch-up amount.
Amendment approved by Compensation Committee and Board of Directors on March 18, 2026.
Employee may elect to receive salary in cash or restricted shares based on closing price.
Amendment filed as Exhibit 10.1 to Form 8-K dated March 18, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.